Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LUPANETA PACK vs ALTAVERA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Leuprolide is a synthetic Gn RH analog that desensitizes pituitary Gn RH receptors, suppressing LH and FSH secretion, leading to decreased sex steroid production (testosterone in males, estrogen in females).
Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.
Endometriosis,Uterine leiomyomata (fibroids),Central precocious puberty,Prostate cancer (palliative treatment),Breast cancer (off-label),Infertility (off-label as part of controlled ovarian hyperstimulation)
Prevention of pregnancy,Treatment of moderate acne vulgaris (in females ≥15 years with no contraindications)
Leuprolide acetate 3.75 mg intramuscularly every month or 11.25 mg intramuscularly every 3 months.
1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.
Terminal elimination half-life is 6-12 hours (mean 8 hours). Clinical context: supports twice-daily dosing; prolonged in severe renal impairment (Cr Cl <30 m L/min).
Levonorgestrel: terminal elimination half-life 25±10 hours; ethinyl estradiol: 13±7 hours. Clinical context: steady-state concentrations achieved within 5-7 days; contraceptive efficacy requires consistent daily dosing.
Leuprolide is primarily metabolized by peptidases and endopeptidases; norethindrone acetate is metabolized via reduction and conjugation (CYP3A4).
Ethinyl estradiol: primarily metabolized by CYP3A4; undergoes sulfation and glucuronidation. Desogestrel: rapidly converted to active metabolite etonogestrel via CYP2C9 and CYP2C19; further metabolism by CYP3A4.
Renal excretion accounts for approximately 50% of the total clearance as unchanged drug, with the remainder undergoing hepatic metabolism followed by biliary/fecal elimination (approx. 30% fecal, 20% biliary).
Renal excretion of metabolites and unchanged drug: ~30% (levonorgestrel) and ~20% (ethinyl estradiol) in urine; biliary/fecal elimination: ~40-50% as conjugates and metabolites.
98% bound to albumin; saturable at high concentrations.
Levonorgestrel: 98-99% bound to sex hormone-binding globulin (SHBG) and albumin; ethinyl estradiol: 98% bound to albumin.
0.2-0.3 L/kg (approx. 15-21 L in 70 kg adult), indicating limited extravascular distribution.
Levonorgestrel: Vd ~1.8 L/kg (suggesting extensive tissue distribution). Ethinyl estradiol: Vd ~2.4 L/kg.
Oral bioavailability: 85-90% (first-pass metabolism minimal).
Oral bioavailability: levonorgestrel ~100% (nearly complete); ethinyl estradiol ~45-50% (first-pass hepatic metabolism).
No dose adjustment is required for renal impairment.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal disease or acute renal failure due to potential fluid retention.
No dose adjustment is required for hepatic impairment.
Contraindicated in severe hepatic dysfunction (Child-Pugh class B or C). Use caution in mild to moderate impairment (Child-Pugh A); monitor liver enzymes.
Not approved for pediatric use.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults (1 tablet daily, 21/7 regimen) after evaluation of risks.
No specific dose adjustment is required; use with caution due to potential comorbidities.
Not indicated for postmenopausal women. No specific geriatric dosing; consider increased risk of thromboembolism, cardiovascular disease, and metabolic effects in older women of reproductive age.
None for Lupaneta Pack specifically, but leuprolide components carry warnings for: (1) Initial tumor flare with transient increase in serum testosterone/estradiol leading to worsening of symptoms in prostate/breast cancer; (2) QT prolongation risk; (3) Hypersensitivity reactions including anaphylaxis.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age (especially >35 years) and with number of cigarettes smoked. Women who use combined hormonal contraceptives should be strongly advised not to smoke.
Bone density loss with prolonged use; QT prolongation (avoid in patients with risk factors); tumor flare at initiation of therapy; anaphylaxis/hypersensitivity; depression; thromboembolic disorders; hepatic/renal impairment; pregnancy (Category X); lactation; hyperglycemia/diabetes; pituitary apoplexy (rare).
Thrombotic disorders: risk of venous thromboembolism (VTE), stroke, myocardial infarction; discontinue if thrombotic event occurs.,Hepatic disease: discontinue if jaundice or liver function abnormalities develop.,Hypertension: monitor blood pressure; discontinue if uncontrolled.,Carbohydrate metabolism: may affect glucose tolerance; monitor diabetic patients.,Depression: discontinue if significant depression occurs.,Gallbladder disease: increased risk of cholelithiasis.
Pregnancy (Category X), lactation, undiagnosed abnormal vaginal bleeding, known or suspected breast cancer (for norethindrone component), thromboembolic disorders, hepatic disease (for norethindrone component), hypersensitivity to Gn RH agonists or any component.
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Estrogen-dependent neoplasia (known or suspected),Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma (known or suspected),Pregnancy (known or suspected),Hypersensitivity to any component
No significant food interactions. Grapefruit juice may slightly increase estrogen levels; avoid large amounts. St. John's wort (herbal supplement) reduces contraceptive efficacy.
No significant food interactions. Alcohol does not affect efficacy but may increase risk of adverse effects such as nausea. Grapefruit juice has no known interaction. Avoid excessive alcohol consumption due to potential hepatotoxicity.
LUPANETA PACK (levonorgestrel/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure: no increased risk of major birth defects beyond background rate; postfertilization effects not expected. Second/third trimester: androgenic effects on female fetus, including clitoral enlargement and labial fusion; possible cardiovascular and limb defects at high doses. Overall risk is low with unintentional early exposure.
ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular defects (relative risk 1.2-1.4) and no consistent increase in other major malformations. Second and third trimesters: No known teratogenic effects, but theoretical risks from estrogenic effects (e.g., feminization of male fetus). Postnatal: No increased risk of long-term developmental effects from pregnancy exposure.
Small amounts of ethinyl estradiol and levonorgestrel excreted in breast milk. M/P ratio for levonorgestrel ~0.37, ethinyl estradiol <0.01. May reduce milk production and quality; use only if benefits outweigh risks. Avoid during established lactation if alternative contraception available.
Combined oral contraceptives may reduce milk production and quality, especially in early lactation. Ethinyl estradiol transfers into breast milk at low levels (M/P ratio approximately 0.1-0.2), excluding clinical effects in term infants. Levonorgestrel transfer is minimal (M/P ratio ~0.2-0.4). Use is generally avoided in breastfeeding women, especially during the first 6 weeks postpartum. Progestin-only methods are preferred.
No dose adjustment recommended because drug is contraindicated in pregnancy. Discontinue immediately if pregnancy occurs. Pharmacokinetic changes in pregnancy (increased clearance of sex hormones) are not applicable due to contraindication.
Contraindicated in pregnancy. No dose adjustment recommended because use is discontinued upon confirmed or suspected pregnancy. Pharmacokinetic changes in pregnancy (e.g., increased hepatic clearance, altered binding proteins) are not relevant for this indication.
LUPANETA PACK is a combined hormonal contraceptive containing estradiol valerate and dienogest. Monitor for thromboembolic events, especially in smokers over 35. Advise use of backup contraception during first 7 days of initiation. Consider CYP3A4 interactions with rifampin, anticonvulsants, and St. John's wort.
ALTAVERA is a combined oral contraceptive (COC) containing ethinylestradiol and levonorgestrel. It inhibits ovulation via suppression of gonadotropins. Counsel patients to take at the same time daily to maintain efficacy. Missed pill management: if missed within 12 hours, take immediately; if >12 hours, take last missed pill and use backup contraception for 7 days. Be aware of increased VTE risk, especially in smokers over 35. May reduce effectiveness of lamotrigine; monitor seizure control. Initiate on the first day of menses or first Sunday after onset.
Take one tablet daily at the same time, in the order specified on the pack, starting on day 1 of menstruation.,Missed dose management: if late by less than 12 hours, take immediately and continue regular schedule; if more than 12 hours, consider backup contraception for 7 days.,Seek emergency care for signs of blood clots: sudden severe headache, chest pain, leg swelling, or vision changes.,Common side effects include nausea, breast tenderness, mood changes, and spotting.,Use additional non-hormonal contraception if taking antibiotics or other interacting medications.
Take one tablet daily at the same time each day, with or without food.,If you miss a pill by less than 12 hours, take it as soon as you remember. If more than 12 hours, take the missed pill and use a backup method (e.g., condoms) for the next 7 days.,Smoking increases your risk of serious cardiovascular side effects, especially if you are over 35 years old. Do not smoke while taking this medication.,Seek immediate medical attention if you experience sudden severe headache, chest pain, leg pain/swelling, or vision changes (symptoms of blood clots).,This medication does not protect against HIV or other sexually transmitted infections.,If you are taking lamotrigine or other anticonvulsants, tell your doctor; your seizure medication may be less effective.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LUPANETA PACK vs ALTAVERA, answered by our medical review team.
LUPANETA PACK is a Oral Contraceptive that works by Leuprolide is a synthetic Gn RH analog that desensitizes pituitary Gn RH receptors, suppressing LH and FSH secretion, leading to decreased sex steroid production (testosterone in males, estrogen in females).. ALTAVERA is a Combined Oral Contraceptive that works by Combination of ethinyl estradiol and desogestrel: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; desogestrel (progestin) causes cervical mucus thickening and endometrial atrophy, preventing implantation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LUPANETA PACK and ALTAVERA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LUPANETA PACK is: Leuprolide acetate 3.75 mg intramuscularly every month or 11.25 mg intramuscularly every 3 months.. The standard adult dose of ALTAVERA is: 1 tablet (ethinyl estradiol 0.03 mg / levonorgestrel 0.15 mg) orally once daily for 21 days, followed by 7 placebo days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LUPANETA PACK and ALTAVERA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LUPANETA PACK is classified as Category C. LUPANETA PACK (levonorgestrel/ethinyl estradiol) is contraindicated in pregnancy. First trimester exposure: no increased risk of major birth defects beyond background rate; postfer. ALTAVERA is classified as Category C. ALTAVERA contains ethinyl estradiol and levonorgestrel. First trimester: Inadvertent exposure during organogenesis is associated with a very low absolute risk of cardiovascular def. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.